Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling

Endocrinology

Volumn 150, Issue 6, 2009, Pages 2857-2864

  Ikeda, Yasumasa ^a   Aihara, Ken Ichi ^a   Yoshida, Sumiko ^a   Sato, Takashi ^b   Yagi, Shusuke ^a   Iwase, Takashi ^a   Sumitomo, Yuka ^a   Ise, Takayuki ^a   Ishikawa, Kazue ^a   Azuma, Hiroyuki ^a   Akaike, Masashi ^a   Kato, Shigeaki ^c,d   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANDROGEN ANDROGEN RECEPTOR SYSTEM; ANDROPAUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THORACIC AORTA; URINARY EXCRETION; VASCULAR FIBROSIS; VASCULAR REMODELING;

ANDROGENS; ANGIOTENSIN II; ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; LIPID PEROXIDATION; MALE; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANDROGEN; SUPEROXIDES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA1; VASOCONSTRICTOR AGENTS;

EID: 66649092912     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1254     Document Type: Article

References (62)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
2. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, Morel L 2004 Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 279: 14579-14586
3. Simoncini T, Genazzani AR 2003 Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148:281-292
4. Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M 2003 Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83:965-1016
5. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S 2003 Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 300:167-171
6. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S 2003 Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100:9416-9421
7. Miyamoto J, Matsumoto T, Shiina H, Inoue K, Takada I, Ito S, Itoh J, Minematsu T, Sato T, Yanase T, Nawata H, Osamura YR, Kato S 2007 The pituitary function of androgen receptor constitutes a glucocorticoid production circuit. Mol Cell Biol 27:4807-4814
8. Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, Cui TX, Horiuchi M 2002 Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 40:451-457; discussion 448-450
9. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
10. van Eickels M, Grohé C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA 2001 17β-Estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104:1419-1423
11. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohé C, van Bilsen M, Doevendans PA 2004 17β-Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation 109:269-276
12. Ogita H, Node K, Liao Y, Ishikura F, Beppu S, Asanuma H, Sanada S, Takashima S, Minamino T, Hori M, Kitakaze M 2004 Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43:237-242
13. Pedram A, Razandi M, Aitkenhead M, Levin ER 2005 Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 280:26339-26348
14. Xu Y, Arenas IA, Armstrong SJ, Davidge ST 2003 Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 57:388-394
15. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M 2005 Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45:545-551
16. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ 1998 Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 98:256-261
17. Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, Suzaki Y, Izawa Y, Fujimura M, Hashizume S, Kato M, Yagi S, Tamaki T, Kawano H, Matsumoto T, Azuma H, Kato S, Matsumoto T 2005 Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 280:29661-29666
18. Lin Jr AL, McGill Jr HC, Shain SA 1982 Hormone receptors of the baboon cardiovascular system. Biochemical characterization of aortic and myocardial cytoplasmic progesterone receptors. Circ Res 50:610-616
19. Horwitz KB, Horwitz LD 1982 Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest 69:750-758
20. Criqui MH 1986 Epidemiology of atherosclerosis: an updated overview. Am J Cardiol 57:18C-23C
21. Mäkinen J, Järvisalo MJ, Pöllänen P, Perheentupa A, Irjala K, Koskenvuo M, Mäkinen J, Huhtaniemi I, Raitakari OT 2005 Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 45:1603-1608
22. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT 2004 Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109:2074-2079
23. Sato T, Matsumoto T, Kawano H, Watanabe T, Uematsu Y, Sekine K, Fukuda T, Aihara K, Krust A, Yamada T, Nakamichi Y, Yamamoto Y, Nakamura T, Yoshimura K, Yoshizawa T, Metzger D, Chambon P, Kato S 2004 Brain masculinization requires androgen receptor function. Proc Natl Acad Sci USA 101:1673-1678
24. Shiina H, Matsumoto T, Sato T, Igarashi K, Miyamoto J, Takemasa S, Sakari M, Takada I, Nakamura T, Metzger D, Chambon P, Kanno J, Yoshikawa H, Kato S 2006 Premature ovarian failure in androgen receptor-deficient mice. Proc Natl Acad Sci USA 103:224-229
25. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M, Matsumoto T 2008 Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 102:68-76
26. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S, Kawai-Kowase K, Moriyama N, Imai Y, Kawakami H, Nishimatsu H, Ishikawa T, Suzuki T, Morita H, Maemura K, Sata M, Hirata Y, Komukai M, Kagechika H, Kadowaki T, Kurabayashi M, Nagai R 2002 Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 8:856-863
27. Aihara K, Azuma H, Akaike M, Ikeda Y, Sata M, Takamori N, Yagi S, Iwase T, Sumitomo Y, Kawano H, Yamada T, Fukuda T, Matsumoto T, Sekine K, Sato T, Nakamichi Y, Yamamoto Y, Yoshimura K, Watanabe T, Nakamura T, Oomizu A, Tsukada M, Hayashi H, Sudo T, Kato S, Matsumoto T 2007 Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest 117:1514-1526
28. Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M 2005 Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension 46:577-583
29. Honda S, Takahashi M, Araki Y, Kakehi K 1983 Postcolumn derivatization of catecholamines with 2-cyanoacetamide for fluorimetric monitoring in high-performance liquid chromatography. J Chromatogr 274:45-52
30. Yamada K, Nabeshima T 1997 Simultaneous measurement of nitrite and nitrate levels as indices of nitric oxide release in the cerebellum of conscious rats. J Neurochem 68:1234-1243
31. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, Hayashi H, Yamada Y, Endoh F, Fujimura M, Yoshida T, Yamaguchi H, Hashizume S, Kato M, Yoshimura K, Yamamoto Y, Kato S, Matsumoto T 2004 Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 279:35798-35802
32. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase T, Kondo A, Matsumoto T 2004 Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 109:2761-2765
33. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG 1996 Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923
34. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW 1994 Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148
35. Zalba G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, Díez J 2001 Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 38:1395-1399
36. Griendling KK, Sorescu D, Lassègue B, Ushio-Fukai M 2000 Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20:2175-2183
37. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE 1990 Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med 323:22-27
38. Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Förstermann U, Meinertz T, Griendling K, Münzel T 2002 Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90:E58-E65
39. Muller M, van der Schouw YT, Thijssen JH, Grobbee DE 2003 Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 88:5076-5086
40. Dubey RK, Oparil S, Imthurn B, Jackson EK 2002 Sex hormones and hypertension. Cardiovasc Res 53:688-708
41. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS 1999 Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 99:2317-2322
42. Ng MK, Quinn CM, McCrohon JA, Nakhla S, Jessup W, Handelsman DJ, Celermajer DS, Death AK 2003 Androgens up-regulate atherosclerosis- related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol 42:1306-1313
43. Adams MR, Williams JK, Kaplan JR 1995 Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15:562-570
44. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C 1999 Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterolfed rabbits. Circ Res 84:813-819
45. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W 2001 Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103:1382-1385
46. Irani K 2001 Angiotensin II-stimulated vascular remodeling: the search for the culprit oxidase. Circ Res 88:858-860
47. Wagner AH, Schroeter MR, Hecker M 2001 17β-Estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J 15:2121-2130
48. Gragasin FS, Xu Y, Arenas IA, Kainth N, Davidge ST 2003 Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol 23:38-44
49. Tam NN, Gao Y, Leung YK, Ho SM 2003 Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 163:2513-2522
50. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F 2000 Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406-5417
51. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC 2003 Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651-1664
52. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, Kreuzer J 2000 Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 20:940-948
53. Shen WL, Gao PJ, Che ZQ, Ji KD, Yin M, Yan C, Berk BC, Zhu DL 2006 NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation. Biochem Biophys Res Commun 339:337-343
54. Massagué J 2000 How cells read TGF-β signals. Nat Rev Mol Cell Biol 1:169-178
55. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY 2006 Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98:1032-1039
56. Kyprianou N, Isaacs JT 1988 Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131
57. Kyprianou N, Isaacs JT 1989 Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522
58. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F, Seki T, Nishizawa M, Fujisawa J, Okazaki K 2005 Transforming growth factor-β and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 166:1029-1039
59. Dzau VJ 1993 The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens 2:27-32
60. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A 1995 Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 26:957-962
61. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A 1997 Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99:278-287
62. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T 2005 Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 112:1701-1710